Risk on bias assessment: (2) Revised Cochrane risk of bias tool for individually randomized, parallel group trials (RoB2.0)
Because microneedle technology reaches deeper skin layers, penetrating the stratum corneum, epidermis, and dermis to reach the capillaries, it can deliver certain medications that transdermal patches cannot
Your body establishes receptor sensitivity to tirzepatide based on consistent weekly exposure, and irregular administration can disrupt this balance
But building a clinical-grade platform one that integrates deeply with real-world pharmacies and physician networksrequires a different standard of care
For people with clinical obesity, the kind that's harming their health, Kushner's message is close to unequivocal: they work, they're disease-modifying, and the lifelong framing is a feature, not a bug